Management and diagnosis of dry eye

Article

The TearLab Osmolarity System is the Gold Standard for diagnosing and managing Dry Eye Disease with a quantitative, objective endpoint.

Dry Eye - Management and diagnosis

The TearLab Osmolarity System is the first objective and quantitative test for diagnosing and managing Dry Eye patients.

  • Provides fast and accurate results in seconds using only 50 nanolitres (nL) of tear film to diagnose Dry Eye Disease
  • Enables discussion with patients around a number, improving compliance
  • Incorporating osmolarity into the standard of care gives the best indication of early stage disease

The TearLab Osmolarity System is intended to measure the osmolarity of tears to aid in the diagnosis of dry eye disease, in conjunction with other methods of clinical evaluation. TearLab is for professional in vitro diagnostic use only.

Hyperosmolarity has been described in the literature as a primary marker of tear film integrity. When the quantity or quality of secreted tears is compromised (known as aqueous deficient or evaporative Dry Eye Disease), increased rates of evaporation lead to a more concentrated tear film (increased osmolarity) that places stress on the corneal epithelium and conjunctiva.

Company name: TearLab Corp
Address: 9980 Huennekens St. Ste. 100 San Diego, California 92121, USA
Telephone: +1 866-877-TEAR
E-mail: sales@tearlab.comWebsite: www.tearlab.com

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Sunita Radhakrishnan, MD, an associate at the Glaucoma Center of San Francisco, speaks at the annual Glaucoma 360 meeting about electrical neurostimulation.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.